A Phase 1, Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of mRNA-6231, Encoding for a Human Serum Albumin - Interleukin-2 Mutein Fusion Protein (HSA-IL2m), in Healthy Adults
Latest Information Update: 16 Aug 2022
At a glance
- Drugs MRNA 6231 (Primary)
- Indications Autoimmune disorders
- Focus Adverse reactions
- Sponsors Moderna Therapeutics
- 09 Aug 2022 Status changed from recruiting to completed.
- 25 May 2022 Planned number of patients changed from 112 to 52.
- 25 May 2022 Planned End Date changed from 15 Nov 2022 to 18 Feb 2023.